Lumiliximab is a Mab able to bind CD23, a low-affinity IgE receptor found to be higly expressed on chronic lymphocytic leukemia (CLL) cells, whereas dacetuzumab (also known as SNG-40) targets CD40, a molecule expressed on several types of B cells neoplasms (18, 19). This evidence concerns the gene CD40 and B-cell chronic lymphocytic leukemia.